BIOGEN INC.
Ticker: BIIBHealthcareBiological ProductsS&P 500The business
Biogen Inc. (NASDAQ: BIIB) is a global biopharmaceutical company headquartered in Cambridge, Massachusetts, with operations across North America, Europe, and international markets. The company website is www.biogen.com.
Biogen focuses on discovering, developing, and delivering innovative therapies for serious and complex diseases, with particular expertise in neurology, specialized immunology, and rare diseases. The company maintains a diversified portfolio of marketed products across multiple therapeutic areas. In neurology, Biogen markets multiple multiple sclerosis treatments including TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI. The company co-developed LEQEMBI with Eisai for Alzheimer's disease treatment and collaborates with Supernus on ZURZUVAE for postpartum depression. In rare diseases, Biogen markets SPINRAZA for spinal muscular atrophy, QALSODY for amyotrophic lateral sclerosis, and SKYCLARYS for Friedreich ataxia. The company also commercializes a portfolio of biosimilars including BENEPALI, IMRALDI, and FLIXABI through collaborations with Samsung Bioepis.
Biogen maintains significant collaborative relationships with leading pharmaceutical and biotechnology companies. The company has agreements with Genentech providing business and financial rights to anti-CD20 therapeutic programs including RITUXAN, GAZYVA, OCREVUS, LUNSUMIO, and COLUMVI. Collaborations with Ionis support development of antisense oligonucleotide therapies for rare neurological diseases.
The company supports its drug discovery and development efforts through internal research and development programs, external collaborations, and strategic acquisitions. Recent acquisitions include Alcyone Therapeutics for implantable drug delivery technology and Reata Pharmaceuticals for rare disease treatments. Biogen's business model emphasizes innovation in addressing unmet medical needs through both organic development and external partnerships, positioning the company as a leader in specialized therapeutic areas with high barriers to entry and significant patient populations requiring advanced treatment options.
- Sector
- Healthcare
- Industry
- Biological Products
- HQ
- CAMBRIDGE, MA
- FY end
- 12-31
- CIK
- 875045
- SIC
- 2836
Ownership
Who holds BIOGEN INC. — across funds, superinvestors and bonds · N-PORT 2026Q2 · 13F 2026-06-30
Top fund holders
| Fund | % of fund | Value |
|---|---|---|
| VANGUARD PRIMECAP FUND VPMCX · VANGUARD CHESTER FUNDS | 1.88% | $1.81B |
| Fidelity Contrafund FCNTX | 0.60% | $1.08B |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VTI · VANGUARD INDEX FUNDS | 0.04% | $1.01B |
| VANGUARD 500 INDEX FUND VOO · VANGUARD INDEX FUNDS | 0.05% | $827.05M |
| VANGUARD MID-CAP INDEX FUND VO · VANGUARD INDEX FUNDS | 0.31% | $691.19M |
Superinvestors in BIOGEN INC.
Share of each manager's reported 13F portfolio.
Bonds held by funds
Funds report holding 7 issues of BIOGEN INC.'s debt, $655.07M at fund-held market value — what funds hold, not the company's debt outstanding. Weighted-average coupon 3.82%, maturing 2030–2055.
| Issue | Coupon | Matures | Funds | Fund-held |
|---|---|---|---|---|
| Biogen, Inc. | 2.250% | 2030-05-01 | 88 | $265.83M |
| Biogen, Inc. | 5.750% | 2035-05-15 | 67 | $106.07M |
| Biogen Inc | 3.150% | 2050-05-01 | 63 | $97.08M |
| Biogen, Inc. | 6.450% | 2055-05-15 | 51 | $74.77M |
| Biogen Inc | 5.050% | 2031-01-15 | 42 | $49.52M |
| Biogen Inc | 3.250% | 2051-02-15 | 50 | $34.37M |
| Biogen Inc | 5.200% | 2045-09-15 | 35 | $27.43M |
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Go deeper in your own AI
15 years of statements, narrative and filings — queryable over MCP.
Professionals can also use the built-in AI chat (subscription + your own Anthropic key).
15 years of BIOGEN INC.'s financials
Income statement, balance sheet and cash flow across 15 years, every filing with its disclosures, and each number traceable to the filing it came from — free with an account, no card required.
Sign in free